NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AIMD

Ainos Inc

Jul 03 • 04:00PM ET

3.29

Dollar change +0.10
Percentage change 3.13	%

Healthcare • Medical Devices • USA • NASD

Peers: MRNA GILD INVA CDMO RGEN ALT URGN VTGN ACHV

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.63	Insider Own	97.14%	Shs Outstand	3.44M	Perf Week	36.46%
Market Cap	13.79M	Forward P/E	-	EPS next Y	-	Insider Trans	-1.11%	Shs Float	0.12M	Perf Month	2.11%
Enterprise Value	23.16M	PEG	-	EPS next Q	-	Inst Own	0.54%	Short Float	34.77%	Perf Quarter	22.99%
Income	-14.83M	P/S	125.36	EPS this Y	-	Inst Trans	54.57%	Short Ratio	0.66	Perf Half Y	44.74%
Sales	0.11M	P/B	0.86	EPS next Y	-	ROA	-52.88%	Short Interest	0.04M	Perf YTD	44.30%
Book/sh	3.81	P/C	5.24	EPS next 5Y	-	ROE	-82.87%	52W High	5.35 -38.50%	Perf Year	-18.31%
Cash/sh	0.63	P/FCF	-	EPS past 3/5Y	15.31% 12.06%	ROIC	-61.50%	52W Low	2.00 64.50%	Perf 3Y	-96.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-67.33% 12.06%	Gross Margin	58.43%	Volatility	13.84% 9.76%	Perf 5Y	-96.66%
Dividend TTM	-	EV/Sales	210.55	EPS Y/Y TTM	57.99%	Oper. Margin	-13072.64%	ATR (14)	0.29	Perf 10Y	-98.67%
Dividend Ex-Date	-	Quick Ratio	1.91	Sales Y/Y TTM	13.38%	Profit Margin	-13967.42%	RSI (14)	62.49	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.00	EPS Q/Q	63.93%	SMA20	18.64%	Beta	2.21	Target Price	-
Payout	-	Debt/Eq	0.91	Sales Q/Q	412.36%	SMA50	17.49%	Rel Volume	0.95	Prev Close	3.19
Employees	44	LT Debt/Eq	0.84	Earnings	-	SMA200	21.83%	Avg Volume	62.90K	Price	3.29
IPO	Aug 08, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	59,999	Change	3.13%

Jun-30-25 08:00AM	Ainos Completes Stock Consolidation, Enters New Phase of Global Expansion and Technology Commercialization (ACCESSWIRE) +13.20%
Jun-27-25 08:00AM	Ainos and ASE Technology Holding Broaden Strategic Partnership to Target Deploy Up to 15,000 AI Nose Across Key Sites (ACCESSWIRE)
Jun-26-25 11:00AM	Ainos Aligns Capital Structure With 2H 2025 Execution Roadmap; Announces Stock Consolidation (ACCESSWIRE)
Jun-24-25 08:00AM	Ainos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia (ACCESSWIRE)
Jun-17-25 11:35AM	Water Tower Research Spotlights Ainos' Advances and Milestones in Digital Olfaction and Healthcare: Entering Inflection Point in 2H25 (ACCESSWIRE) +5.84%
08:00AM	Loading…
Jun-16-25 08:00AM	Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy (ACCESSWIRE)
Jun-03-25 08:00AM	Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter (ACCESSWIRE)
May-29-25 08:00AM	Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80% (ACCESSWIRE) -6.52%
May-22-25 08:00AM	Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner (ACCESSWIRE)
May-19-25 08:00AM	Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy (ACCESSWIRE)
May-14-25 08:00AM	Water Tower Research Highlights Ainos' Significant Commercial Traction and Strategic Milestones Across Multiple Sectors (ACCESSWIRE)
May-12-25 08:00AM	Ainos Reports First Quarter 2025 Financial Results (ACCESSWIRE)
Apr-30-25 08:12AM	Ainos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart Manufacturing (ACCESSWIRE)
Apr-23-25 08:00AM	Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly (ACCESSWIRE)
Apr-21-25 08:00AM	Ainos and ugo Complete First Robotic Smell Integration in Japan (ACCESSWIRE)
08:00AM	Loading…
Apr-14-25 08:00AM	Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjogren's Syndrome in Taiwan (ACCESSWIRE) -9.72%
Apr-11-25 08:00AM	Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling (ACCESSWIRE) +23.08%
Mar-24-25 05:00PM	Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025 (ACCESSWIRE)
Mar-13-25 09:00AM	Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Noses Potential in Chip Manufacturing and More (ACCESS Newswire)
Mar-11-25 09:00AM	Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing (ACCESSWIRE)
Mar-07-25 04:45PM	Ainos Reports Full Year 2024 Financial Results (ACCESSWIRE) -5.89%
01:30PM	Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here (ACCESSWIRE)
Mar-06-25 10:11AM	Ainos, ugo to develop robot with sense of smell (TipRanks)
Mar-05-25 10:00AM	Ainos and ugo to Develop the World's First Robot With a Sense of Smell (ACCESSWIRE)
Jan-27-25 10:00AM	Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation (ACCESSWIRE)
Jan-21-25 10:00AM	Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025 (ACCESSWIRE)
Jan-17-25 09:00AM	Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule (ACCESSWIRE)
Jan-13-25 10:00AM	Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots (ACCESSWIRE) -18.30%
Dec-18-24 12:05PM	CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA (ACCESSWIRE)
08:00AM	Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA (ACCESSWIRE)
08:00AM	Loading…
Dec-13-24 08:00AM	Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement (ACCESSWIRE) -7.35%
Dec-04-24 08:00AM	Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing (ACCESS Newswire)
Dec-02-24 08:00AM	Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sj gren's Syndrome Drug (Newsfile) -8.28%
Nov-13-24 08:00AM	Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments (ACCESSWIRE)
Nov-11-24 08:00AM	Ainos Announces IRB Approval for Sjögrens Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 (ACCESS Newswire)
08:00AM	Ainos Announces IRB Approval for Sjogren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 (ACCESSWIRE)
Nov-08-24 08:00AM	Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities (ACCESSWIRE)
Nov-06-24 04:30PM	Ainos Reports Third Quarter 2024 Financial Results (ACCESSWIRE) +14.67% -5.33%
Oct-28-24 08:00AM	Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets (ACCESSWIRE)
Oct-24-24 10:50AM	Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast (ACCESSWIRE)
Oct-07-24 08:00AM	Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies (ACCESSWIRE)
Sep-25-24 08:00AM	Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA (ACCESSWIRE) +18.26%
Sep-24-24 10:55AM	Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome (ACCESSWIRE)
Sep-23-24 08:00AM	Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options (ACCESSWIRE)
08:00AM	Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjogren's Syndrome, a Rare Disease With Limited Treatment Options (ACCESSWIRE)
Sep-20-24 08:00AM	Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts (ACCESSWIRE) -5.68%
Sep-17-24 08:00AM	Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA (ACCESSWIRE)
Sep-03-24 08:30AM	Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention (ACCESSWIRE)
Aug-27-24 08:30AM	Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Aug-26-24 08:30AM	Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter (ACCESSWIRE) +6.09%
Aug-19-24 09:15AM	Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety (GlobeNewswire)
Aug-12-24 08:00AM	Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024 (ACCESSWIRE) +8.06%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-09-24 04:15PM	Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing (ACCESSWIRE)
Aug-06-24 07:30AM	Ainos Concludes Growth Financing From Lind Partners (ACCESSWIRE) -6.49%
Aug-05-24 04:15PM	Ainos Reports Second Quarter 2024 Financial Results (ACCESSWIRE) -17.06%
Jul-23-24 08:30AM	Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug (ACCESSWIRE)
Jun-14-24 08:00AM	Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA (ACCESSWIRE) +7.29%
May-15-24 08:00AM	Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market (ACCESSWIRE)
May-13-24 09:54PM	AIMD Stock Earnings: Ainos Reported Results for Q1 2024 (InvestorPlace)
04:10PM	Ainos Reports First Quarter 2024 Financial Results (ACCESSWIRE)
May-07-24 08:00AM	Ainos Raises $9 Million in Growth Capital with Existing Shareholder (ACCESSWIRE)
Mar-08-24 04:20PM	Ainos Reports Full Year 2023 Financial Results (ACCESSWIRE) +83.04% -20.00%
07:58AM	Why Is Ainos (AIMD) Stock Up 153% Today? (InvestorPlace)
Mar-04-24 08:22AM	Why Is Ainos (AIMD) Stock Up 57% Today? (InvestorPlace) +35.24%
Feb-08-24 08:35AM	Small-Cap Growth Virtual Investor Conference Presentations Now Available for Online Viewing (GlobeNewswire)
Feb-06-24 09:51AM	Small-Cap Growth Virtual Investor Conference Agenda Announced for February 7th, 2024 (GlobeNewswire) -7.81%
Feb-05-24 09:00AM	Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms (ACCESSWIRE)
Feb-01-24 08:35AM	Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th (GlobeNewswire)
Jan-24-24 09:00AM	Ainos Announces $1.75 Million Follow-On Funding (ACCESSWIRE) -10.34%
Jan-05-24 08:08AM	Why Is Ainos (AIMD) Stock Up 157% Today? (InvestorPlace) +58.38%
Jan-02-24 09:00AM	Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE) -6.34%
Dec-26-23 09:00AM	Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell (ACCESSWIRE)
Dec-14-23 05:52AM	AIMD Stock Earnings: Ainos Reported Results for Q1 2023 (InvestorPlace)
Dec-12-23 08:00AM	Ainos, Inc. Announces Stock Consolidation (ACCESSWIRE)
Nov-28-23 08:30AM	Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical (ACCESSWIRE)
Nov-21-23 08:30AM	Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA (ACCESSWIRE)
Nov-09-23 04:30PM	Ainos Reports Third Quarter 2023 Financial Results (ACCESSWIRE)
Nov-06-23 08:00AM	Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA (ACCESSWIRE)
Sep-25-23 08:30AM	Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement (ACCESSWIRE)
Sep-19-23 12:26PM	With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients (Newsfile)
Sep-18-23 07:00AM	Ainos VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients (ACCESSWIRE) -21.30%
Sep-05-23 07:00AM	Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan (ACCESSWIRE)
Aug-15-23 01:29PM	Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond (Newsfile)
Aug-11-23 04:30PM	Ainos Reports Second Quarter 2023 Financial Results (ACCESSWIRE) +5.14%
Aug-10-23 08:00AM	Ainos Celebrates First Listing Anniversary on Nasdaq (ACCESSWIRE) -7.16%
Aug-09-23 08:00AM	Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption (ACCESSWIRE) -6.49%
Jun-27-23 08:30AM	Ainos Issues Mid-Year Business Update Letter to Shareholders (ACCESSWIRE)
Jun-20-23 08:30AM	Ainos Provides Insights Into Its AI Nose Technology (ACCESSWIRE) -7.97%
Jun-14-23 09:00AM	Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target (ACCESSWIRE)
Jun-07-23 09:00AM	Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target (ACCESSWIRE) +5.20%
May-30-23 09:00AM	Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales (ACCESSWIRE)
May-17-23 04:30PM	Ainos Appoints Amanda Sung as New Chief Financial Officer (ACCESSWIRE) -5.14%
May-12-23 04:15PM	Ainos Reports First Quarter 2023 Financial Results (ACCESSWIRE)
Mar-31-23 05:50PM	Ainos Reports Fourth Quarter and Full Year 2022 Financial Results (ACCESSWIRE)
Mar-21-23 07:00AM	Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan (ACCESSWIRE) -16.13%
Mar-14-23 07:00AM	Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients (ACCESSWIRE) +79.17%
Mar-13-23 04:30PM	Ainos Announces US$3 Million Convertible Notes Private Placement (ACCESSWIRE) +5.88%
Jan-23-23 07:00AM	Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug (ACCESSWIRE) -7.42%
Jan-17-23 07:00AM	Ainos Issues 2023 Shareholder Letter (ACCESSWIRE)

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its medtech solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded on June 26, 1984 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
lee ting-chuan	Director	Jun 25 '25	Sale	0.51	2,894	1,476	1,428,538	Jun 27 04:15 PM
TSAI CHUN-JUNG	Director	Jun 27 '25	Sale	0.50	10,000	5,020	1,384,997	Jun 27 04:15 PM
TSAI CHUN-JUNG	Director	Jun 25 '25	Sale	0.50	7,000	3,520	1,394,997	Jun 27 04:15 PM
TSAI CHUN-JUNG	Director	Jun 19 '25	Sale	0.55	10,903	6,015	1,411,997	Jun 23 07:44 PM
TSAI CHUN-JUNG	Director	Jun 23 '25	Sale	0.50	10,000	5,000	1,401,997	Jun 23 07:44 PM
TSAI CHUN-JUNG	Director	Jun 18 '25	Sale	0.52	5,000	2,609	1,422,900	Jun 23 07:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIMD

Ainos Inc

Upgrade your FINVIZ experience